Development of a cardiopulmonary support system with excellent antithrombogenicity and durability that enables continuous long-term perfusion with minimum anticoagulant therapy

点击翻译按钮获取中文摘要

We have develop a new ECMO system which has an excellent antithrombogenicity and durability, aiming at facilitating prolonged ECMO support using newly developed heparin bonding technique (T-NCVC), a newly-developed membrane oxygenator (Platinum Cube NCVC), and a long-term durable centrifugal blood pump. Our results indicated that our newly developed ECMO system possesses a potential to perform prolonged circulatory support with minimum anticoagulants. In the evaluation using animals, all the ECMO systems could be maintained in the stable condition at least up to 65 days without systemic anticoagulants. All the animals except for one were able to be preserved until scheduled termination of experiments. No serum leakage from the oxygenators was observed, and the gas exchange performance was constantly retained. The pump performance was also sustained to deep purposed blood flow, and no significant hemolysis was observed. The changes of blood components and coagulation relating factors were ranged within quite small extent, which indicates that this ECMO system provides high blood compatibility. This ECMO system is an innovative system which has a potential to realize long-term perfusion without anticoagulants and device exchanges. It will realize the improvement of clinical results in the treatment of severe respiratory and/or circulatory distress patients, and furthermore, this system should change the concept of ECMO due to its long-term durability and high antithrombogenicity, especially in the application for such patients with difficulty in the anticoagulant therapy.